MiR-501-3p functions as a tumor suppressor in non-small cell lung cancer by downregulating RAP1A

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The role of microRNA-501-3p (miR-501-3p) in non-small cell lung cancer (NSCLC) is currently unknown.
• Previous studies suggest tumor-suppressive functions for miR-501-3p in other cancer types.

Purpose of the Study:

• To investigate the expression pattern and biological function of miR-501-3p in NSCLC.
• To elucidate the underlying molecular mechanism of miR-501-3p's action in NSCLC.
• To evaluate the potential of miR-501-3p as a diagnostic or therapeutic target for NSCLC.

Main Methods:

• Quantitative real-time PCR to assess miR-501-3p expression in NSCLC tissues and cell lines.
• In vitro functional assays (proliferation, clonogenicity, migration, invasion) to evaluate the effects of miR-501-3p.
• In vivo tumor growth assays in a nude mouse model.
• Western blotting and luciferase reporter assays to identify and validate miR-501-3p targets.
• Correlation analysis between miR-501-3p and target gene expression in clinical NSCLC samples.

Main Results:

• miR-501-3p was significantly downregulated in NSCLC tissues and cell lines compared to normal controls.
• Overexpression of miR-501-3p inhibited NSCLC cell proliferation, clonogenicity, migration, and invasion.
• miR-501-3p overexpression suppressed tumor growth in vivo.
• RAP1A was identified as a direct target of miR-501-3p, and its overexpression counteracted the tumor-suppressive effects of miR-501-3p.
• A negative correlation was observed between miR-501-3p levels and RAP1A expression in NSCLC clinical samples, with RAP1A being upregulated.

Conclusions:

• miR-501-3p functions as a tumor suppressor in NSCLC.
• The tumor-suppressive role of miR-501-3p is mediated through direct targeting of RAP1A mRNA.
• miR-501-3p may serve as a potential theranostic biomarker for NSCLC patients.